Humanigen Inc (HGENQ)

[cowtown jay]

eb, I have just sent the following to the Project Manager at AB Data Ltd.


Re: [External]Exclusion from Litigation


Jay Booth

From:
[e-mail]
To:
Ann Cavanaugh

Sat, Feb 3 at 6:15 PM

Dear Ms. Cavanaugh.

Your instruction that I must send a letter by mail, and that I must provide transaction details in Humanigen securities, to be excluded from litigation, impose requirements that I don't feel well enough to comply with. I will simply comply with page 2 of the Notice of Pendency:

"DO NOTHING Get no payment."

I strongly disagree with the Lead Counsel, as I have publicly declared in the following.

cowtown jay

Re: bencozey post# 41218

Tuesday, December 19, 2023 7:38:43 PM

Post#
41220
of 41817 Go
As the ACTIV-5 government-sponsored trial of lenzilumab was announced, I felt that it was nothing more than the commandeering of our successful LIVE-AIR trial results. A simple comparison of the trial designs prove that. Look at the patient inclusion criteria for the two trials.

The government-sponsored ACTIV-5 trial inclusion criteria #6:

"Illness of any duration, and requiring, just prior to randomization, supplemental oxygen (any flow), mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) (ordinal score 5, 6, or 7)."

https://clinicaltrials.gov/study/NCT04583969?intr=Lenzilumab&rank=2

The company-sponsored LIVE-AIR trial inclusion criteria:

"SpO2 ≤ 94% on room air and/or require low-flow supplemental oxygen and/or require high-flow oxygen support or NIPPV
Hospitalized, not requiring invasive mechanical ventilation during this hospitalization"

https://clinicaltrials.gov/study/NCT04351152?intr=Lenzilumab&rank=3

The government excluded room air patients in their trial, and included patients on IMV and ECMO. Humanigen did not intend to treat patients that were as seriously ill as the government included in their trial.

And in case you haven't seen just how successful the LIVE-AIR trial results were, here are the peer reviews from Lancet and Thorax on this page.

Humanigen, Inc.

I've been here since 2017. I know the company hoped that ACTIV-5 would corroborate our findings. But including patients in such a late-stage of disease progression in their trial, and excluding the room air patients who did so well in the LIVE-AIR trial, only demonstrates that ACTIV-5 was never going to corroborate the LIVE-AIR trial results.

Lenzilumab is going to be a blockbuster drug (generate over $1B in yearly revenue). Pfizer needs that revenue. But we don't need Pfizer, or any other Big Pharma, to capture this market potential. Durrant has already run 5 blockbuster products through the FDA validation process. And Dale is a specialist in the field of T cell memory function, having been published in his post-doctoral work with the Howard Hughes Medical Institute.

I have shown you the proof of what this management team has done. And I have demonstrated the government's effort to safeguard the revenue of their Big Pharma sponsors. Hopefully, facts will persuade you that the NIH and the FDA are the real culprits here, with the deadly abuse of their discretionary authority."


Thank you,
Jay Booth